Axsome Therapeutics Inc
NASDAQ:AXSM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
59.18
99.49
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AXSM stock under the Base Case scenario is 89.67 USD. Compared to the current market price of 97.83 USD, Axsome Therapeutics Inc is Overvalued by 8%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Axsome Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AXSM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Axsome Therapeutics Inc
Balance Sheet Decomposition
Axsome Therapeutics Inc
Current Assets | 463m |
Cash & Short-Term Investments | 315.7m |
Receivables | 120.3m |
Other Current Assets | 27m |
Non-Current Assets | 85.2m |
PP&E | 6.8m |
Intangibles | 28.3m |
Other Non-Current Assets | 50.1m |
Current Liabilities | 186.6m |
Accounts Payable | 61.3m |
Accrued Liabilities | 118.2m |
Other Current Liabilities | 7m |
Non-Current Liabilities | 258.8m |
Long-Term Debt | 182.4m |
Other Non-Current Liabilities | 76.4m |
Earnings Waterfall
Axsome Therapeutics Inc
Revenue
|
291.5m
USD
|
Cost of Revenue
|
-28.3m
USD
|
Gross Profit
|
263.2m
USD
|
Operating Expenses
|
-568.9m
USD
|
Operating Income
|
-305.7m
USD
|
Other Expenses
|
-2.8m
USD
|
Net Income
|
-308.6m
USD
|
Free Cash Flow Analysis
Axsome Therapeutics Inc
USD | |
Free Cash Flow | USD |
AXSM Profitability Score
Profitability Due Diligence
Axsome Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Axsome Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
AXSM Solvency Score
Solvency Due Diligence
Axsome Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Axsome Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AXSM Price Targets Summary
Axsome Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AXSM is 126.23 USD with a low forecast of 71.71 USD and a high forecast of 189 USD.
Dividends
Current shareholder yield for AXSM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 108 full-time employees. The company went IPO on 2015-11-19. The firm is engaged in developing therapies for the management of central nervous system (CNS) disorders. The firm's core CNS portfolio includes four CNS product candidates, AXS-05, AXS-07, AXS-12, and AXS-14, which are being developed for multiple indications. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral, rapidly absorbed and multi-mechanistic investigational medicine under development for the acute treatment of migraine. AXS-07 consists of Molecular Solubility Enhanced Inclusion Complex (MoSEIC), meloxicam and rizatriptan. AXS-12, reboxetine, is an oral, investigational medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine, is an oral, investigational medicine in development for the treatment of fibromyalgia.
Contact
IPO
Employees
Officers
The intrinsic value of one AXSM stock under the Base Case scenario is 89.67 USD.
Compared to the current market price of 97.83 USD, Axsome Therapeutics Inc is Overvalued by 8%.